- Home
- RZLT
RZLT
Rezolute Inc. (NV)
as 03-28-2025 4:00pm EST
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $12.00 | AVG Volume (30 days): | 667.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.22 - $6.19 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Rezolute Inc. (NV) (RZLT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Evans Daron | RZLT | CFO | Mar 26 '25 | Buy | $2.89 | 20,000 | $57,700.00 | 237,900 | |
| Hogenhuis Wladimir | RZLT | Director | Feb 16 '25 | Buy | $4.70 | 10,000 | $47,000.00 | 77,267 |
Latest Rezolute Inc. (NV) News
RZLT Breaking Stock News: Dive into RZLT Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors
GlobeNewswire
2 months ago
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Simply Wall St.
2 months ago
Rezolute Insiders Placed Bullish Bets Worth US$557.5k
GlobeNewswire
2 months ago
Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
GlobeNewswire
2 months ago
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference
GlobeNewswire
3 months ago
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
GlobeNewswire
4 months ago
Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
4 months ago
FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Compare RZLT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RZLT Rezolute Inc. (NV) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.